Horizon Therapeutics, a subsidiary of Amgen, has announced plans to implement layoffs at its facility located in Rockville, Maryland. This decision will affect 22 employees, who are to receive a notice period of 60 days in accordance with the Worker Adjustment and Retraining Notification (WARN) Act.
Details of the Layoffs
On March 9, 2026, Horizon Therapeutics USA, Inc. filed a WARN notice detailing the upcoming layoffs scheduled to commence on May 8, 2026. The facility, located at 9605 Medical Center Drive, Suite 325, will see the termination of positions without the prospect of recall, indicating a permanent separation for the affected workers.
Background on Horizon Therapeutics and Amgen
Horizon Therapeutics is renowned for its focus on developing treatments for rare and rheumatic diseases. The company was acquired by Amgen in October 2023 for $27.8 billion, integrating Horizon’s innovative programs and therapies into the broader research and commercial initiatives of Amgen.
Amgen is a leading multinational biotechnology firm engaged in the discovery, development, production, and delivery of novel human therapeutics. The company addresses serious health concerns across various fields, including oncology, cardiovascular disease, inflammation, and rare diseases. With research and manufacturing facilities in multiple countries, Amgen employs a significant workforce as part of its global biopharmaceutical operations.
Implications for the Biopharmaceutical Sector
The WARN filing highlights the ongoing uncertainty surrounding employment within the biopharmaceutical sector. This dynamic industry is characterized by rapid changes in skill requirements and product demand, which can lead to fluctuations in job roles and employment stability.
As professionals in the biopharmaceutical field navigate these transitions, it is crucial for stakeholders to consider avenues for support and retraining. The ability to adapt to an evolving landscape is essential for sustaining career trajectories within this innovative sector.